The leading AL Amyloidosis Companies such as Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, ZENTALIS ...

Manipulating the immune system to treat cancer has generated phenomenal responses in some patients, including complete cures, ...

SGH will process cord blood to develop and produce allogeneic chimeric antigen receptor (CAR) T-cells designed for cancer ...

Laboratories International announced an agreement with Singapore General Hospital SGH to provide Current Good Manufacturing ...

A new study from researchers at the University of Leipzig Medical Center and collaborators, has discovered a rare but serious ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Clinical Director Dr Robert Weinkove says ‘site activation’ in Christchurch and Auckland marks a significant milestone for the clinical trial, and means more patients can be treated, closer to home.

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T ...

Few advancements in contemporary medicine have sparked as much enthusiasm and potential as CAR T-cell therapy.

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.

Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...

Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers ...